Inclusion Criteria:

          1. Histologically or cytologically confirmed metastatic or unresectable locally
             advanced/metastatic NSCLC

          2. Documented evidence of a tumor with activating EGFR mutations by local testing.
             Patients with exon 20 insertions are not eligible with the exception of patients with
             documented evidence of the exon 20 insertion A763_Y764insFQEA in the EGFR gene

          3. Have undergone a biopsy or surgical resection of either primary or metastatic tumor
             tissue within 60 days of the first day of study treatment, C1D1, and have tissue
             available to send to sponsor laboratories or are able to undergo a biopsy during
             screening and provide tissue to sponsor laboratories

          4. Measureable disease according to RECIST Version 1.1

          5. Life expectancy of at least 3 months

          6. ECOG (Eastern Cooperative Oncology Group) performance status of 0 to 1

          7. Minimum age 18 years (in certain territories, the minimum age requirement may be
             higher (e.g. 20 years in Japan and Taiwan)

          8. Adequate hematological and biological function, confirmed by defined laboratory values

          9. Written consent on an IRB/IEC-approved Informed Consent Form (ICF) prior to any
             study-specific evaluation

        Exclusion Criteria:

          1. Documented evidence of an exon 20 insertion activating mutation other than
             A763_Y764insFQEA in the EGFR gene

          2. Prior treatment with cytotoxic chemotherapy for advanced NSCLC; neoadjuvant/adjuvant
             chemotherapy is permitted if at least 6 months has elapsed between the end of
             chemotherapy and randomization

          3. Active second malignancy; i.e., patient known to have potentially fatal cancer present
             for which he/she may be (but not necessarily) currently receiving treatment

          4. Patients with a history of malignancy that has been completely treated, and currently
             with no evidence of that cancer, are permitted to enroll in the trial provided all
             chemotherapy was completed > 6 months prior and/or bone marrow transplant > 2 years
             prior to first day of study treatment

          5. Known pre-existing interstitial lung disease

          6. Brain metastases

          7. Treatment with prohibited medications less than or equal to 14 days prior to first day
             of study treatment

          8. Patients who are currently receiving treatment with any medications that have the
             potential to prolong the QT interval if that treatment cannot be either discontinued
             or switched to a different medication prior to administration of study drug

          9. Prior treatment with EGFR TKIs (e.g. erlotinib, gefitinib, neratinib, afatinib,
             AZD9291, or dacomitinib), rociletinib or other drugs that target mutant EGFR

         10. Clinically significant abnormal 12-lead ECG, QT interval corrected using Fridericia's
             method (QTCF) > 450 ms

         11. Inability to measure QT interval on ECG

         12. Personal or family history of long QT syndrome

         13. Implantable pacemaker or implantable cardioverter defibrillator

         14. Resting bradycardia < 55 beats/min

         15. Non-study related surgical procedures less than or equal to 7 days prior to
             administration of study drug. In all cases, the patient must be sufficiently recovered
             and stable before treatment administration.

         16. Females who are pregnant or breastfeeding

         17. Refusal to use adequate contraception for fertile patients (females and males) for 12
             weeks after the last dose of rociletinib and 2 weeks after the last dose of erlotinib

         18. Presence of any serious or unstable concomitant systemic disorder incompatible with
             the clinical study

         19. Any other reason the investigator considers the patient should not participate in the
             study